The Future...

Discussion in 'Dey' started by Anonymous, Apr 19, 2014 at 12:07 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Curious to what the direction at Mylan Specialty is? Is EpiPen going generic in 2015? Will we have a new product to promote before then? Future of Perforomist along with Combo coming out in 2016?

    Consider this...Sunovian will be launching a combo close to that time, and hopefully not before us. What ever happened in the lawsuit outcome? What was the outcome? Mylan won the case but what were the details? It's brilliant on Mylans part when you think about it. If they get a % in royalties from Brovana and potentially the combo when it launches, they have Perforomist and Brovana coming in as profit, but only paying commissions to Perforomist.

    Also, like any generic company...push, push, push until the end. But when Teva does launch another competitor in the market, if and when that happens, what is the next move? Will they treat it like any other generic product and move on? Will they still need a sales force. Is there another product waiting in the wings? Co-promotion?

    And speaking of that...for Gods Sake, 9 and 4? Seriously? Here's an idea, why not allow us to sell products into our markets using all the data we have? I know in the "traditional" big pharma world you bulk the numbers up to look good for a potential co-promotion. But seriously, someone in upper management, grow some balls and come up with an original, outside the box sales plan that will attract another company.

    So, what is the future at Mylan Specialty?
     

  2. Anonymous

    Anonymous Guest

    We are all dumber for reading this... The fukin direction is crystal clear make Epi a Billion dollar Rx and launch the combo... In that order dipsh!t!
     
  3. Anonymous

    Anonymous Guest

    Best post of the year
     
  4. Anonymous

    Anonymous Guest



    How's this going with the growth of the generic? What happens when Epi goes off patent and before the combo launches? Serious questions to think about...
     
  5. Anonymous

    Anonymous Guest

    you cant tell me you wake up in the morning and ACTUALLY get excited to...never mind. inept minds enjoy obtuse environments.
     
  6. Anonymous

    Anonymous Guest

    The sales force is going to end up just like Basking Ridge Home Office!!! Extinct

    Please see the pattern because your are all kidding yourself if u think HB will keep 300 reps to sell a $70mill LABA.

    The building is burning, get out now if you a smart enough to see it for what it is!!!
     
  7. Anonymous

    Anonymous Guest

    No she is planning on selling the real epipen vs the exact same cheaper generic version when it launches. Also now that epipen is hitting 1 Billion dollars our bonus is going up by 3k! That's 1500 American dollars after taxes, who isn't motivated now?
     
  8. Anonymous

    Anonymous Guest


    Yep, makes no sense unless they buy a company with branded products. How can anyone believe the BS that a generic wouldn't matter?
     
  9. Anonymous

    Anonymous Guest

    DONT FORGET YOUR CYANKIT!!! THAT WAS ANOTHER WINNER! HA!!!
     
  10. Anonymous

    Anonymous Guest

    I'm not positive but I would say with 99% certainty that there has never been a blockbuster $1 Billion dollar product that was promoted with just 300 reps. Hell, I used to be on a sales team of 10,000 reps to promote a $2 billion product. There has never been a more efficient sales team in the world to produce this kind of result.

    According to my math- we are averaging $3.33 million in Epipen sales per rep this year. Think about that number for a minute. At 8 calls per day and roughly 47 weeks of work per year after vacation and meetings- that is about 1,900 calls per year. Or about $1,700 in revenue per call. If you figure that the average rep costs Mylan $150,000 per year (all in with salary, bonus, car, insurance...), the cost per call is about $78. Lets get crazy and add $200 per call for other over head like management, advertising, support staff- $278 per call to get $1,700 in sales is a NICE return.

    Even with this track record- If we don't have anything more to sell than Perforomist after
    Epipen goes generic... the ax will fall. To stay on pace for our EPS target, we will need to slash costs to make up for the loss in revenue. You don't need an MBA to know that the easiest cost to cut is labor. That is why every large corporation down sizes with each down turn in revenue. They get the costs off the books and a bump in share price when they announce it.

    Mylan leadership won't like doing it. At all. But when it is us or them to file into the unemployment line- it is a difficult but simple decision.
     
  11. Anonymous

    Anonymous Guest

    What's going on with the deal for the Abbott mature product line?
     
  12. Anonymous

    Anonymous Guest

    All stock deal you dope, better tax rate and they still have cash on hand for an acquisition supporting US based generic and specialty units.
     
  13. Anonymous

    Anonymous Guest

    Better hope they buy something specialty can sell in the next 12 months.
     
  14. Anonymous

    Anonymous Guest

    Do you like the new Auvi -Q DTC campaign and national commercials?
     
  15. Anonymous

    Anonymous Guest

    Yes, love then, epipen is DEAD and so are you!
     
  16. Anonymous

    Anonymous Guest

    Seriously?? You think that 300 reps are solely responsible for the total sales of epipen? First of all, it had limited or no competition for a very long time. 2ndly, what is the Marketing spend? $50 million? Tons of DTC, commercials, digital, etc. Managed Markets access is probably the biggest contributor! 300 reps are a small part of the equation. Now do the math.


     
  17. Anonymous

    Anonymous Guest

    The dopes will be proven wrong. Go back to selling your failed insulin product fat body. Sanofi will be done with you by year end
     
  18. Anonymous

    Anonymous Guest

    Exactly. If you're fortunate enough to have a DEY Rep from pre 2007 around, ask them about the history of Duoneb. The managers either lied or didn't tell the Reps the truth and we found out online that Duoneb went generic. The managers were so upset that we found out! We were to sell the 2 in 1 bennys to the end. Then, DEY began making a generic, sold to make revenue off of that then made the reps 'pay' for not beating the generic….Accuneb…died and Epi just began to get it's first competitor with TwinJect. Many of us had to move on. Duoneb was the business. Think strategically-bc the company sure is… best of luck.
     
  19. Anonymous

    Anonymous Guest

    so are you implying that perforomist could go away or be ignored further? this brand is what gets people to win president club.
     
  20. Anonymous

    Anonymous Guest

    How many times did you hear P-mist at the NSM or at POA? How many times did you here Epi will be a 1B dollar product. Enough Said!